Anti-CD19 chimeric-antigen receptor T cells (CART19) have shown high response rates and durable remissions in relapsed/refractory(r/r) B-cell acute lymphoblastic leukaemia (B-ALL) and non-Hodgkin lymphoma (NHL) [65]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.